Building a diversified biotech portfolio of CAR
Wellington Zhaotai Therapies is the global (excluding Greater China) commercialisation entity for Hunan Medical Group's and the Malaghan Institute of Medical Research's CAR T- cell therapies.
Combined, Wellington Zhaotai Therapies has more than 130 hundred employees engaged in biotechnology research and technology and clinical trials.
Highlights of our cell therapy capabilities
CAR T–cell therapy Phase I trials targeting B-ALL lymphoma, lung cancer, liver cancer, pancreatic cancer, gastric cancer with nine construct designs being trialled (China).
Multiple pre-clinical china trials in B-ALL lymphoma, multiple myeloma and acute myeloid leukaemia (China).
CAR T–cell therapy Phase I trials targeting non Hodgkin Lymphoma (New Zealand).
GMP facilities for viral construct and biopharmaceutical manufacture (China, New Zealand).